about us


We are focused on the clinical development of novel therapies for cancer. Our programs include a potential best-in-class HDAC inhibitor, Pracinostat, and isoflavone-based compounds ME-143 and ME-344.
[ Read more ]

latest news

MEI Pharma CEO to Present at Needham Healthcare Conference
[ April 23, 2013 ] [ Webcast ]

ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model
[ April 10, 2013 ] [ Poster ]

MEI Pharma Announces $15.2 Million Registered Offering of Common Stock
[ April 5, 2013 ]

MEI Pharma Adds Tom Reynolds to Board of Directors
[ February 11, 2013 ]

Marshall Edwards Announces Name Change to MEI Pharma (“MEIP”)
Click here for our 2012 Annual Report